Teladoc Health (TDOC)
(Delayed Data from NYSE)
$6.94 USD
-0.27 (-3.74%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $6.95 +0.01 (0.14%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TDOC 6.94 -0.27(-3.74%)
Will TDOC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TDOC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TDOC
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
Teladoc (TDOC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
TDOC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Teladoc (TDOC) Reports Q2 Loss, Beats Revenue Estimates
HIMS vs. TDOC: Which Direct-to-Consumer Health Stock Wins Now?
CVS Health (CVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Other News for TDOC
Decoding Teladoc Health Inc (TDOC): A Strategic SWOT Insight
Teladoc Health: Still Struggling To Find A Catalyst
Biggest stock movers Wednesday: SBUX, SOFI, NVO, LC, and more
Teladoc (TDOC) Price Target Reduced by Cantor Fitzgerald Analyst
Teladoc price target lowered by $2 at Cantor Fitzgerald, here's why